The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-02-06
DOI
10.1093/annonc/mdz047
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene
- (2018) Yanchun Li et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
- (2018) Michail Ignatiadis et al. JNCI-Journal of the National Cancer Institute
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
- (2018) Michail Ignatiadis et al. JNCI-Journal of the National Cancer Institute
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Gene expression markers of Tumor Infiltrating Leukocytes
- (2017) Patrick Danaher et al. Journal for ImmunoTherapy of Cancer
- Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
- (2017) Ahrong Kim et al. Scientific Reports
- Improved Survival of HER2+Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain
- (2016) Keith L. Knutson et al. CANCER RESEARCH
- Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
- (2016) Edith A. Perez et al. JAMA Oncology
- Natural and therapy-induced immunosurveillance in breast cancer
- (2015) Guido Kroemer et al. NATURE MEDICINE
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
- (2015) Sara M. Tolaney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
- (2014) Torsten Nielsen et al. BMC CANCER
- Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing
- (2012) Nirmala Pathmanathan et al. BREAST
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started